Goldman Sachs analysts added Baxter (BAX) to the firm’s US Conviction List as part of its monthly update. The firm expects a turnaround in shares after a long period of underperformance catalyzed by the company’s “stable,” mid-single-digit, revenue growth, “significant” operating margin expansion and free cash flow growth. Goldman has a Buy rating on Baxter with a $42 price target
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BAX: